Human, animal & cell studies

CJC-1295 with DAC

Albumin binding extends CJC-1295 exposure. Short human studies recorded sustained GH and IGF-I responses while preserving pulse structure.

Research summary

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.

The Journal of clinical endocrinology and metabolism 2006

Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA

Healthy-adult pharmacology study

Growth hormone and IGF-I remained elevated for several days after DAC-bearing CJC-1295 in healthy adults. Two short, placebo-controlled studies estimated a half-life of roughly six to eight days, consistent with its albumin-binding design. The observations describe the DAC preparation’s pharmacology and do not supply a duration estimate for CJC-1295 without DAC.

View on PubMed

Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.

The Journal of clinical endocrinology and metabolism 2006

Ionescu M, Frohman LA

Healthy-adult pharmacology study

Growth-hormone pulses remained evident during prolonged stimulation by CJC-1295 with DAC. Healthy men had higher trough and mean growth-hormone concentrations and higher IGF-I one week after administration, while pulse frequency and magnitude were unchanged. This distinguishes a raised endocrine baseline from an increase in pulse frequency, within one short observation window.

View on PubMed

Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.

Endocrinology 2005

Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP

Cellular and animal mechanistic research

Albumin-conjugated GHRH analogues retained activity in pituitary cells and resisted degradation. The selected CJC-1295 preparation produced prolonged exposure and a larger growth-hormone response than the comparison fragment in rats. Its reactive albumin-binding group is therefore part of the mechanism and must be distinguished from no-DAC compounds.

View on PubMed

Models studied

Pharmacokinetic profile
Growth-hormone secretion patterns
IGF-I response
Growth-hormone pulsatility

Key findings

How albumin binding extends exposure
Albumin conjugation preserved receptor-linked activity while changing exposure and degradation, separating DAC pharmacology from no-DAC material.
Human endocrine duration
The several-day endocrine response and roughly six-to-eight-day half-life belong to the albumin-binding preparation.
Pulses versus baseline secretion
A higher hormonal baseline occurred without more frequent or larger GH pulses in the short human observation window.

References

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
The Journal of clinical endocrinology and metabolism 2006
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA
PMID 16352683
View on PubMed: Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.
The Journal of clinical endocrinology and metabolism 2006
Ionescu M, Frohman LA
PMID 17018654
View on PubMed: Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.
Endocrinology 2005
Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP
PMID 15817669
View on PubMed: Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.

For laboratory research use only. Content is provided for research reference and is not intended as medical or veterinary guidance.

10% off your first order

Search compounds, blends or categories

CJC-1295 with DAC

Research summary

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.

Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.

Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.

Models studied

Key findings

How albumin binding extends exposure

Human endocrine duration

Pulses versus baseline secretion

References

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.

Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.

Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.